NEURACAP
Sector OutlookPublished · 21 pages · Free to read

Contract Development and Manufacturing (CDMO) Sector Outlook — September 2026

A sector-wide review of the 11 listed contract development and manufacturing companies, covering EV/Revenue (CY2027E) valuation, recorded precedent transactions, and the operating choices tied to price. Built for owners, acquirers and boards assessing CDMO positioning and capacity strategy.

For information only. Not an appraisal or a fairness opinion.

What moved since: Contract Development and Manufacturing (CDMO) M&A update, 14–28 September 2026

Key figures

Sector median EV/Revenue
6.2x
CY2027E consensus, 6 of 11 rated
Top pair EV/Revenue
16.5x
CY2027E revenue
Bottom pair EV/Revenue
0.9x
CY2027E revenue
Demand-side share of listed set
73%
clinical-stage innovators of 11 names

Read the report

NeuraCap

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO)

CDMO: The Premium Sits with Capability

How the listed names in contract development and manufacturing are priced today, and what the recorded transactions show buyers agreed to pay.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice

1

1 / 21

Executive summary

Across 11 listed CDMO names, valuation splits by business model: clinical-stage innovators make up 73% of the set, while two sterile capacity names anchor a separate segment. On EV/Revenue (CY2027E), the sector median sits at 6.2x, with the top pair trading at 16.5x against 0.9x for the bottom pair — a spread that runs inside the innovator group as well as across it. Recorded precedent transactions reach $21.8B in size and up to 17.6x on earnings multiples, pointing to a premium buyers have paid for evidenced capability.

Key findings

  • Eight of 11 listed names sell outsourcing demand; two sell sterile capacity.
  • Top pair trades at 16.5x CY2027E revenue vs 0.9x for the bottom pair.
  • Sector median sits at 6.2x CY2027E revenue, the primary valuation lens.
  • Precedent deals reach $21.8B, far above listed-name scale.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO)

    This is the cover for NeuraCap's September 2026 CDMO sector outlook, framed on EV/Revenue (CY2027E) valuation as of 2026-09-28.

    We're opening our September 2026 look at contract development and manufacturing, built on EV/Revenue (CY2027E) as the primary valuation lens. The pages that follow lay out where the eleven listed names sit today and what recorded transactions show buyers have paid — so what's ahead is the full pricing picture in one deck.

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) CDMO: The Premium Sits with Capability How the listed names in contract development and manufacturing are priced today, and what the recorded transactions show buyers agreed to pay. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This slide lists the report's five numbered sections plus the appendix.

    We've structured this report in five sections plus an appendix, starting with the bottom line so a reader who stops there still gets the whole story. From there we move through the market landscape, valuation and situations, precedent transactions and strategic implications. So what: you can go as deep as you need, but the headline sits on page one.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Contract Development and Manufacturing: Price Sits with Capability Rather than with Size 02 The Landscape Most of the Listed Set Sells into Outsourcing Demand Rather than Running the Suites 03 Valuation & Situations Two Names Hold the Top of the Range and Two Hold the Bottom 04 Precedent Transactions Sponsors and Strategic Buyers Have Both Been Active for Capacity and for Services 05 Strategic Implications A Wide Range Leaves Room to Move Within It, and Revenue Mix, Pricing and Margin Are the Moves That Matter 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Contract Development and Manufacturing: Eight Innovator Names, Two Sterile Capacity Names, One Wide Price Range

    This slide summarizes the full pricing story: eight innovator names, two sterile capacity names and one wide valuation range.

    We start with the headline: across the eleven listed CDMO names, eight sell into outsourcing demand and two run sterile capacity, and the price range between them is wide. Our primary lens is EV/Revenue on CY2027E consensus, with six of eleven names eligible after the platform's plausibility gates. That range — from the low single digits to the mid-teens — is the story the rest of the deck unpacks. So what: where a name sits in that range tells you what buyers believe about its capability, not just its size.

    Everything on this page

    01 · THE BOTTOM LINE Contract Development and Manufacturing: Eight Innovator Names, Two Sterile Capacity Names, One Wide Price Range The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (6 of 11 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Two Ends of the Range Sell Different Things Across the 6 names with a forward revenue estimate, the middle of the top pair sits at 16.5x CY2027E revenue against 0.9x for the bottom pair. Both of the top pair sit in the clinical-stage innovator group, so the spread runs inside one group as well as between groups. 2 Most of the Listed Set Sits on the Demand Side 8 of the 11 listed names, 73% of the set, are clinical-stage innovators on the outsourcing demand side, and the middle of that group sits at 9.9x CY2027E revenue. Two names run sterile injectable and finished dose capacity, and one sits in agricultural chemical inputs. 3 Revenue Is the Working Lens, and It Already Credits Forecast Growth The middle of the set sits at 6.2x CY2027E revenue. Revenue is the lead lens given that only 2 of the 11 names carry a meaningful forward EBITDA, too few to form a middle figure; a forward multiple already credits forecast growth, so a premium that survives it points to durability rather than to one year's forecast. 4 Whole-Business Deals Run Far Above the Listed Names in Size Recorded transactions reach $21.8B for Danaher Corporation's completed purchase of the Biopharma Business, and earnings multiples where recorded include 17.6x for UDG Healthcare plc. Several entries are recorded as announced rather than completed, so read them as terms agreed. 6.2x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because only 2 of 11 names carry a meaningful forward EBITDA 16.5x Premium end EV/Revenue vs 0.9x at the discount end top quartile (n=2) against bottom quartile (n=2) on EV/Revenue — the spread the report explains 18 Transactions with disclosed terms 62 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This divider introduces section two, on how the listed set splits across three business groups.

    This section maps the eleven listed names into three groups that sell to different buyer bases. Most of the set sells outsourcing services rather than running physical manufacturing suites themselves. So what: understanding which group a name sits in is the first step before comparing its price to anyone else's.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Most of the Listed Set Sells into Outsourcing Demand Rather than Running the Suites Three groups under one sector label, selling to different buyer groups. 02 of 06 Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Three Groups Under One Sector Label, Selling to Different Buyer Groups

    This slide groups the 11 approved companies into business segments with a median EV/Revenue (CY2027E) for each group.

    We've grouped all eleven approved companies by what they actually sell, not just their sector label, and shown the median EV/Revenue for each group. The groupings separate clinical-stage innovators, sterile capacity operators and one adjacent chemistry name. So what: comparing a company only to the sector average hides which buyer group it's really competing for.

    Everything on this page

    02 · MARKET MAP Three Groups Under One Sector Label, Selling to Different Buyer Groups 11 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 ADJACENT: CLINICAL-STAGE INNOVATORS (OUTSOURCING DEMAND SIDE) 8 cos median 9.9x Maravai (MRVI) MeiraGTx Holdings (MGTX) MacroGenics (MGNX) Zura Bio Limited (ZURA) Codexis (CDXS) eXoZymes (EXOZ) Lyell Immunopharma (LYEL) TScan Therapeutics (TCRX) The customers for outsourced capacity, 8 of the 11 listed names, and the group where forward estimates are most often available. STERILE INJECTABLE AND FINISHED DOSE MANUFACTURING 2 cos no rated names Lifecore (LFCR) BGM Group (BGM) The capacity-for-hire businesses, where fill-finish and aseptic work means earnings move with suite utilisation against a fixed GMP cost base. ADJACENT: AGRICULTURAL CHEMICAL INPUTS 1 cos 0.4x · 1 rated BioHarvest (BHST) A single adjacent name whose chemistry serves a different end market, and it prices on a different basis.

  6. 06
    02 · LANDSCAPE

    The Listed Set Is Weighted to the Demand Side, and the Capacity Names Are Thin on Coverage

    This slide shows the segment view of the listed universe, noting that capacity names have thinner analyst coverage.

    The listed set leans heavily toward the demand side — companies that outsource to capacity providers rather than run the suites themselves. Coverage on the sterile capacity names is thinner, which limits how far we can push forward-looking multiples for that group. So what: the public market read-across for capacity assets is inherently more limited, and that's a data point in itself.

    Everything on this page

    02 · LANDSCAPE The Listed Set Is Weighted to the Demand Side, and the Capacity Names Are Thin on Coverage Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Adjacent: clinical-stage innovators (outsourcing demand side) 8 73% 9.9x Maravai LifeSciences Holdings, Inc. (MRVI) · MeiraGTx Holdings plc (MGTX) · +6 more Eight names on the demand side. These are the innovators whose molecules fill other people's suites, and their order books are weighted to clinical phases. The middle of the group sits at 9.9x CY2027E revenue, and 5 of the 8 carry a forward estimate, so this is where the listed read-across is widest. Sterile injectable and finished dose manufacturing 2 18% — Lifecore Biomedical, Inc. (LFCR) · BGM Group Ltd. (BGM) Two names running real capacity. Lifecore Biomedical, Inc. (LFCR) and BGM Group Ltd. (BGM) are 18% of the listed set and neither carries a CY2027E revenue estimate here. For owners of fill-finish and aseptic assets, the pricing signal comes from the transaction record more than from these two listed peers. Adjacent: agricultural chemical inputs 1 9% 0.4x n=1 BioHarvest Sciences Inc. Common Stock (BHST) One adjacent chemistry name. BioHarvest Sciences Inc. Common Stock (BHST) is 9% of the set and sits at 0.4x CY2027E revenue. It is a reminder that the sector label gathers businesses whose end markets, contracts and buyers differ from regulated pharmaceutical supply.

  7. 07
    SECTION 03

    03

    This divider introduces section three, on public market valuation across the six rated names.

    This section drills into EV/Revenue (CY2027E) across the six names with a forward revenue estimate. Two names hold the top of the range and two hold the bottom, and we unpack what separates them. So what: the valuation spread itself is evidence for what the market is willing to pay a premium for.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS Two Names Hold the Top of the Range and Two Hold the Bottom CY2027E EV / Revenue across the 6 names with a forward revenue estimate. 03 of 06 Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    The Top Pair, the Middle Pair and the Bottom Pair Sell Different Things

    This slide ranks the six rated companies by EV/Revenue (CY2027E), sorted descending, against a sector median of 6.2x.

    We've sorted all six rated companies by EV/Revenue (CY2027E), and the sector median sits at 6.2x. The top pair, middle pair and bottom pair each sell a distinguishable story to the market, not just a different size. So what: revenue is the lens that matters here, since only two of eleven names carry a meaningful forward EBITDA estimate.

    Everything on this page

    03 · PUBLIC MARKET VALUATION The Top Pair, the Middle Pair and the Bottom Pair Sell Different Things EV / Revenue (CY2027E) · all 6 rated companies, sorted descending · sector median 6.2x · EV/Revenue is the lens because only 2 of 11 names carry a meaningful forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (6 of 11 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 16.5x CORE · median 6.2x DISCOUNT · median 0.9x Sector median 6.2x WHAT SEPARATES THE TWO ENDS The top pair is clinical-stage. Zura Bio Limited (ZURA) and MeiraGTx Holdings plc (MGTX) sit at the top of the range, with the middle of that pair at 16.5x CY2027E revenue. A forward multiple already credits forecast growth, so a price holding at that level points to durability rather than to a single year's estimate. The bottom pair reports revenue today. Codexis, Inc. (CDXS) and BioHarvest Sciences Inc. Common Stock (BHST) sit at the bottom of the range, with the middle of that pair at 0.9x CY2027E revenue. Their prices sit alongside revenue that is already being delivered, where forecasts can be checked against what the business has shipped. Growth does not sort the ends. Among the 6 names with a forward revenue estimate, BioHarvest Sciences Inc. Common Stock (BHST) grows 37% and sits at the bottom of the range, while Zura Bio Limited (ZURA) grows 12% and sits at the top. On this sample the premium sits alongside what each business sells rather than with the growth rate.

  9. 09
    03 · VALUATION DRIVERS

    What the Prices Here Sit Alongside: Utilisation Evidence, Mix and Filing Switching Costs

    This slide splits the rated names into growth and margin cohorts and shows the median EV/Revenue (CY2027E) for each.

    We've split the rated names by revenue-growth and by EBITDA-margin cohorts to see what the pricing sits alongside. These are associations we observe in the data, not causal claims. So what: mix, growth and margin evidence are the variables worth tracking as a company's price moves within its cohort.

    Everything on this page

    03 · VALUATION DRIVERS What the Prices Here Sit Alongside: Utilisation Evidence, Mix and Filing Switching Costs Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=0; slower n=0; higher-margin n=0; lower-margin n=0). Driver readings are NeuraCap views on the supplied data — association, not causation. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 Reported Profitability Is Thin Where It Shows up at All Of the 6 names with a forward revenue estimate, 2 report an EBITDA margin: Maravai LifeSciences Holdings, Inc. (MRVI) at 20% and BioHarvest Sciences Inc. Common Stock (BHST) at 6%, against a covered middle of 13%. In a business absorbing a fixed GMP cost base through suite utilisation, that gap is the operating-leverage story in one line. Growth in This Set Runs in Both Directions Among the names carrying a growth estimate, the figures run from 37% at BioHarvest Sciences Inc. Common Stock (BHST) and 19% at Codexis, Inc. (CDXS) to -1% at TScan Therapeutics, Inc. (TCRX) and -18% at MacroGenics, Inc. (MGNX). An order book weighted to early clinical phases can move on a single programme decision. A Molecule Written into a Filing Does Not Move Cheaply Once a process and a site are named in a registered filing, moving the work means a tech transfer and re-qualification, and the switching cost outlives the contract term. That durability is diligenced directly in this sector and it does not show up in a growth rate. The Capacity Names Here Are Not Priced on the Forward Lens Sterile injectable and finished dose manufacturing is 2 of the 11 listed names, 18% of the set, and neither carries a CY2027E revenue estimate. Owners of validated fill-finish capacity should expect their benchmark to come from precedent transactions rather than from these listed peers.

  10. 10
    03 · SITUATION MAP

    Two Names Carry Both a Price and a Margin, and Buyers Rate One Well Above the Other

    This slide maps names on EV/Revenue against the sector median of 6.2x and EBITDA margin against the covered median of 13%.

    We've placed each name with both a valuation multiple and a margin figure onto a simple grid: EV/Revenue against the 6.2x sector median, margin against the 13% covered median. Two names carry both measures, and the market rates them differently. So what: this is where price and fundamentals meet, and it's a starting point for the questions that follow, not a recommendation.

    Everything on this page

    03 · SITUATION MAP Two Names Carry Both a Price and a Margin, and Buyers Rate One Well Above the Other Cut on EV / Revenue vs the sector median (6.2x) (rows) and EBITDA margin vs the covered median (13%) (columns) · 4 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Priced up and Profitable Above-median multiple · above-median EBITDA margin 1 names Maravai LifeSciences Holdings, Inc. (MRVI) Maravai LifeSciences Holdings, Inc. (MRVI) is the one of the 2 mapped names sitting above the middle on both the forward revenue multiple and EBITDA margin. This is the corner where utilisation is converting a fixed GMP cost base into reported profit, with the price sitting above the middle alongside it. Priced up, Margin Not yet There Above-median multiple · below-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Profitable, Priced Below the Middle Below-median multiple · above-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Below the Middle on Both Below-median multiple · below-median EBITDA margin 1 names BioHarvest Sciences Inc. Common Stock (BHST) BioHarvest Sciences Inc. Common Stock (BHST) sits below the middle on both, at 0.4x CY2027E revenue against a 6% margin, on the 2 names in this set carrying both figures. It is the single name classified under agricultural chemical inputs, so its end market differs from regulated pharmaceutical supply.

  11. 11
    03 · THE AGENDA

    The Operating Choices Associated with the Top and the Bottom of This Range

    This slide frames the operating choices, as questions, associated with the top and bottom of the valuation range.

    We turn the pricing evidence into questions an owner or acquirer should be resolving now: what drives the premium at the top, and what's missing at the bottom. These are our observations grounded in the data shown, not investment recommendations. So what: the range gives you a checklist for where to focus operating attention next.

    Everything on this page

    03 · THE AGENDA The Operating Choices Associated with the Top and the Bottom of This Range NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Turn Reserved Capacity into Filled Capacity The distance between capacity reserved and capacity filled is where a fixed GMP cost base becomes operating leverage. Of the 6 names with a forward revenue estimate, 2 report an EBITDA margin at all, so evidenced fill stands out inside this set. What changes the answer: Suite utilisation and batch success rates holding through a full campaign cycle. Shift Mix Toward Commercial-Phase Molecules Revenue weighted to early clinical phases carries attrition that a commercial supply agreement does not. Clinical-to-commercial conversion is the operating record that turns molecules on file into contracted volume. What changes the answer: A molecule moving from clinical supply into validated commercial supply on your site. Work Down Single-Customer and Single-Molecule Concentration Concentration in this industry is read both ways: a quality signal about the customer, and a risk to earnings if one programme moves. Pricing, contract structure and the order book are the levers that change the balance. What changes the answer: A second or third anchor customer reaching a take-or-pay reservation on the same suites. Settle Build-Versus-Buy on Fill-Finish Capability The transaction record shows strategic buyers adding finished dose alongside drug substance, and sponsors assembling multi-site networks. The choice is whether to fund commissioning and validation internally or to acquire capacity already inspected and filed. What changes the answer: A carve-out reaching the market with a multi-year supply agreement attached.

  12. 12
    SECTION 04

    04

    This divider introduces section four, on precedent transactions recorded between December 2016 and November 2022.

    This section turns to the transaction record: sponsors and strategic buyers have both been active, in capacity and in services. Several deals are recorded as announced rather than completed. So what: the precedent set shows what buyers have actually agreed to pay, a different lens from the public market multiples we just covered.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Sponsors and Strategic Buyers Have Both Been Active for Capacity and for Services Nine transactions recorded between Dec-2016 and Nov-2022, several recorded as announced. 04 of 06 Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12

  13. 13
    04 · DEAL CASE STUDIES

    What Buyers Agreed to Pay for Capacity, Services and Process Capability

    This slide presents three case studies from the transactions with disclosed terms, with multiples on LTM financials at announcement.

    We've picked three transactions with disclosed terms and walked through what buyers paid for capacity, services and process capability. These multiples are on LTM financials at announcement, so they aren't directly comparable to the CY2027E public basis we used earlier — no spread is implied. So what: these case studies show the reasoning buyers used, which is the more durable takeaway than the multiple alone.

    Everything on this page

    04 · DEAL CASE STUDIES What Buyers Agreed to Pay for Capacity, Services and Process Capability 3 of 18 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 66 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 44 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Nov-2022 $932M Thoma Bravo, L.P. Thoma Bravo, L.P. steps into National Resilience, Inc., a biomanufacturing network built for onshore supply. EV / LTM revenue 6.2x EV / LTM EBITDA 5.3x WHY THE DEAL HAPPENED A financial sponsor taking on regulated manufacturing capacity follows the buy-and-build pattern this sector sees repeatedly: fragmented sites brought under shared quality systems. The transaction suggests validated GMP capacity and supply security were underwritten as contracted infrastructure rather than as a growth story. HOW THE TARGET WAS VALUED The recorded terms are $932M, with 6.2x on revenue and 5.3x on earnings, shown as recorded in the filing. Against the other earnings multiples on this page, which run into the mid-to-high teens, the earnings multiple here sits well below them. Jun-2019 $360M Paragon Gene Therapy Paragon Gene Therapy buys into Novavax, Inc., recorded at $360M in Jun-2019. EV / LTM revenue 22.5x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The buyer is a gene therapy manufacturer and the target sits on the innovator side, so the transaction suggests process capability and capacity were the attraction rather than installed scale. In this sector, buying a modality footprint is often the alternative to the lead times required to design, build, commission and validate one. HOW THE TARGET WAS VALUED The record shows 22.5x on revenue against the recorded value, the top of the revenue multiples on this page. Multiples at that level are conventionally paired with milestone and royalty participation rather than plain upfront consideration. May-2016 $358M Albany Molecular Research, Inc. acquires Prime European Therapeuticals EV / LTM revenue 1.4x EV / LTM EBITDA 13.3x WHY THE DEAL HAPPENED Value shown as recorded in the filing; deal value unit unresolved. HOW THE TARGET WAS VALUED The filing records $358M of enterprise value, struck at 1.4x LTM revenue.

  14. 14
    SECTION 05

    05

    This divider introduces section five, on strategic implications for owners, acquirers and boards.

    This section takes the pricing and transaction evidence and turns it into read-across for three audiences: owners, buyers and boards. A wide valuation range leaves room to move within it. So what: the moves that matter are operating ones — mix, pricing and margin — not the range itself.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS A Wide Range Leaves Room to Move Within It, and Revenue Mix, Pricing and Margin Are the Moves That Matter Read-across for owners, for buyers and for boards. 05 of 06 Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14

  15. 15
    05 · STRATEGIC IMPLICATIONS

    A Range This Wide Leaves Room to Move, and the Moves Are Operating Ones

    This slide lays out the strategic implications for owners, acquirers and boards over the next twelve months.

    We've translated the valuation range into a set of operating questions for owners, acquirers and boards to work through over the next twelve months. Revenue quality, earnings multiples on precedent deals and the thinness of listed capacity comparables each point to a different lever. So what: the room this range leaves is real, but capturing it takes an operating decision, not a market call.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS A Range This Wide Leaves Room to Move, and the Moves Are Operating Ones NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Revenue Quality Is Where the Range Gives You Room Of the 6 names with a forward revenue estimate, 2 report an EBITDA margin, so demonstrated conversion of reserved capacity into filled, validated suites stands out within this set. Mix, contract structure and concentration are the levers that sit inside management's control between now and the next planning cycle. FOR ACQUIRERS What Buyers Agreed to Pay Has Run in the Mid-to-High Teens on Earnings Four of the 9 transactions on this page carry earnings multiples in the mid-to-high teens, from 15.1x to 18.3x, recorded between Dec-2016 and May-2021, across both sponsor and strategic buyers. Several are recorded as announced, so they are terms agreed rather than settled outcomes. FOR BOARDS The Listed Read-Across Is Thin for Capacity Assets Neither of the sterile injectable and finished dose names carries a forward revenue estimate in this set, so the benchmark for validated capacity comes from precedent transactions. Board discussion is better spent on inspection history, filing switching costs and capex phasing than on the listed price range alone.

  16. 16
    SECTION 06

    06

    This divider introduces the appendix, covering the full comparable universe, methodology and sources.

    This closing section carries the full comparables universe, the complete precedent transaction list, and the methodology behind every figure in the deck. So what: any number in this report can be traced back to its source from here.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16

  17. 17
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This appendix slide lists all 11 companies' EV/Revenue (CY2027E) comparables, grouped by valuation tier.

    We've laid out all eleven companies here, the six rated on EV/Revenue (CY2027E) shaded by tier against the 6.2x sector median, and the five without an eligible multiple listed alongside. So what: this is the full underlying comparable set behind every valuation figure used earlier in the deck.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (6.2x); amber marks below · 6 rated companies; 5 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 6 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥14.1x · median 16.5x · 2 companies Zura Bio Limited ZURA Adjacent: clinical-stage innovators (outsourcing… $163M 17.4x 13% n/a n/a MeiraGTx Holdings plc MGTX Adjacent: clinical-stage innovators (outsourcing… $1.0B 15.5x n/a n/a n/a CORE — 1.7x–14.1x · median 6.2x · 2 companies Maravai LifeSciences Holdings, Inc. MRVI Adjacent: clinical-stage innovators (outsourcing… $2.2B 9.9x 7% 20% 26 MacroGenics, Inc. MGNX Adjacent: clinical-stage innovators (outsourcing… $228M 2.5x -18% n/a n/a DISCOUNT — <1.7x · median 0.9x · 2 companies Codexis, Inc. CDXS Adjacent: clinical-stage innovators (outsourcing… $131M 1.5x 19% n/a n/a BioHarvest Sciences Inc. Common Stock BHST Adjacent: agricultural chemical inputs $22M 0.4x 37% 6% 44

  18. 18
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix slide lists precedent transactions with disclosed terms, newest first, the first of two pages.

    We've listed every precedent transaction with disclosed terms here, newest first, drawn from a larger recorded set. Deal multiples are LTM at announcement and are not directly comparable to the CY2027E public basis used elsewhere in this deck. So what: this is the full evidentiary base behind the deal case studies shown earlier.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 18 transactions with disclosed terms in this tier (62 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 66 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 44 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Nov-2022 Thoma Bravo, L.P. → National Resilience, Inc. $932M 6.2x 5.3x Thoma Bravo, L.P. agreed terms for National Resilience, Inc. in Nov-2022, recorded at 5.3x earnings and shown as announced. Financial sponsors in this sector conventionally underwrite contracted, regulated capacity as infrastructure-like. May-2021 Clayton Dubilier & Rice, LLC → UDG Healthcare plc n/a n/a 17.6x Clayton Dubilier & Rice, LLC agreed terms for UDG Healthcare plc in May-2021, recorded at 17.6x earnings and shown as announced. It is a services platform rather than a plant, and it is diligenced on contracts rather than on suites. Feb-2021 W.R. Grace & Co.-Conn. → Fine Chemistry Services business (unit of Fine Chemistry Services business) $570M n/a n/a W.R. Grace & Co.-Conn. completed the purchase of the Fine Chemistry Services business (unit of Fine Chemistry Services business) in Feb-2021 at $570M as recorded. Carve-outs of this kind customarily travel with a multi-year supply agreement and transitional services… Jul-2020 JAB Holding Co. → Sera Labs, Inc. n/a n/a 18.3x JAB Holding Co. agreed terms for Sera Labs, Inc. in Jul-2020, recorded at 18.3x earnings and shown as announced. The buyer sits outside the traditional manufacturing pools, which widens the set of bidders an owner may meet. Jul-2019 Noice Rx, LLC → Harrow Health, Inc. $218M 4.5x n/a Noice Rx, LLC agreed terms for Harrow Health, Inc. in Jul-2019, recorded at $218M and 4.5x revenue, shown as announced. It sits at the lower end of the revenue multiples recorded on this page. Jun-2019 Paragon Gene Therapy → Novavax, Inc. $360M 22.5x n/a Paragon Gene Therapy agreed terms recorded at $360M and 22.5x revenue for Novavax, Inc. in Jun-2019, shown as announced. That is the top of the recorded revenue multiples on this page. Feb-2019 Danaher Corporation → Biopharma Business $21.8B n/a n/a Danaher Corporation completed the purchase of the Biopharma Business in Feb-2019 at $21.8B as recorded. A transaction of that size is about modality and franchise ownership, and it sets the backdrop against which the listed names here are small. Nov-2018 Platinum Equity → Lonza America Inc. n/a n/a 16.7x Platinum Equity agreed terms for Lonza America Inc. in Nov-2018, recorded at 16.7x earnings and shown as announced. Sponsors in this sector favour buy-and-build, consolidating single-site operators into multi-site networks with shared quality systems. Dec-2016 Lonza Group AG → Capsugel S.A. n/a n/a 15.1x Lonza Group AG agreed terms for Capsugel S.A. in Dec-2016, recorded at 15.1x earnings and shown as announced. Strategic buyers here transact to fill modality and geographic gaps across drug substance and drug product.

  19. 19
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix slide continues the precedent transaction list with disclosed terms, newest first.

    This second page completes the disclosed-terms transaction list, continuing newest first from the prior page. As before, these multiples sit on LTM financials at announcement and are shown as recorded in the filings. So what: together the two pages give a client the complete disclosed-terms record to check any deal referenced in this report.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 18 transactions with disclosed terms in this tier (62 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 66 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 44 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jun-2016 Partners Group → PCI Pharma Services n/a n/a 10.5x May-2016 Albany Molecular Research, Inc. → Prime European Therapeuticals $358M 1.4x 13.3x Value shown as recorded in the filing; deal value unit unresolved. Apr-2016 Recipharm AB → Kemwell n/a 0.7x 14.3x Jul-2014 PCI Pharma Services → Penn Pharmaceutical Services Limited n/a n/a 16.2x Oct-2013 Nordic Capital / Avista Capital Partners / Ardian → Acino Holding AG n/a n/a 11.8x Dec-2012 Mitsubishi Chemical Holdings → Qualicaps n/a n/a 10.3x Aug-2012 BC Partners, The Carlyle Group L.P. → Aenova n/a n/a 11.2x Apr-2011 Kohlberg Kravis Roberts & Co L.P. → Capsugel S.A. n/a n/a 10.9x Jan-2007 The Blackstone Group → Cardinal Health PTS (Catalent) n/a n/a 10.3x

  20. 20
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This slide explains the report's sources, valuation basis, exclusions and data-quality flags.

    We close with the methodology: how this report was built, what was excluded and why, and where every underlying disclosure lives. Figures without a direct link are sourced and explained here instead. So what: this page is the reference point for any figure in the deck a client wants to verify independently.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice 20 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (6 of 11 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Contract Development and Manufacturing (CDMO) and it clears the coverage gate with 8 of 11 companies (73%). EV / EBITDA is carried as a cross-check. A revenue lens is used rather than a profit multiple because only 2 of 11 companies carry a meaningful forward EBITDA, too few to form a median. DATA QUALITY & EXCLUSIONS 49 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 314 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (313) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  21. 21

    Across These 11 Listed Names, the Firmer Prices Sit with Evidenced Capability.

    This closing slide restates the report's conclusion: firmer prices sit with evidenced capability across the 11 listed names.

    Across these eleven listed names, the firmer prices sit with evidenced capability — utilisation, mix and process track record, not just scale. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace. So what: that's the standard worth applying to any name in this set going forward.

    Everything on this page

    Across These 11 Listed Names, the Firmer Prices Sit with Evidenced Capability. NeuraCap AI — Contract Development and Manufacturing (CDMO) Coverage September 2026 · Prepared by NeuraCap AI · Confidential Contract Development and Manufacturing (CDMO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21

Sources and methodology

This report covers Contract Development and Manufacturing (CDMO) (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Contract Development and Manufacturing (CDMO)) with market data and consensus estimates as of September 28, 2026. The company universe is the 11 listed companies whose core business is Contract Development and Manufacturing (CDMO) according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: BGM Group Ltd. (BGM), BioHarvest Sciences Inc. Common Stock (BHST), Codexis, Inc. (CDXS), eXoZymes, Inc. (EXOZ), Lifecore Biomedical, Inc. (LFCR), Lyell Immunopharma, Inc. (LYEL), MacroGenics, Inc. (MGNX), MeiraGTx Holdings plc (MGTX), Maravai LifeSciences Holdings, Inc. (MRVI), TScan Therapeutics, Inc. (TCRX), Zura Bio Limited (ZURA). The market map groups them by business vertical — Adjacent: clinical-stage innovators (outsourcing demand side): 8 companies (MRVI, MGTX, MGNX, ZURA, CDXS, EXOZ, LYEL, TCRX); Sterile injectable and finished dose manufacturing: 2 companies (LFCR, BGM); Adjacent: agricultural chemical inputs: 1 company (BHST). 6 of the 11 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Contract Development and Manufacturing (CDMO) (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Contract Development and Manufacturing (CDMO)) with market data and consensus estimates as of September 28, 2026. The company universe is the 11 listed companies whose core business is Contract Development and Manufacturing (CDMO) according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: BGM Group Ltd. (BGM), BioHarvest Sciences Inc. Common Stock (BHST), Codexis, Inc. (CDXS), eXoZymes, Inc. (EXOZ), Lifecore Biomedical, Inc. (LFCR), Lyell Immunopharma, Inc. (LYEL), MacroGenics, Inc. (MGNX), MeiraGTx Holdings plc (MGTX), Maravai LifeSciences Holdings, Inc. (MRVI), TScan Therapeutics, Inc. (TCRX), Zura Bio Limited (ZURA). The market map groups them by business vertical — Adjacent: clinical-stage innovators (outsourcing demand side): 8 companies (MRVI, MGTX, MGNX, ZURA, CDXS, EXOZ, LYEL, TCRX); Sterile injectable and finished dose manufacturing: 2 companies (LFCR, BGM); Adjacent: agricultural chemical inputs: 1 company (BHST). 6 of the 11 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

49 records failed a validation gate and never feed a statistic in this report (44 excluded from aggregate; 5 quarantined). Each exclusion, with its reason: BHST — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BHST — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BHST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BHST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BHST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BHST — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CDXS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CDXS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CDXS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CDXS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CDXS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CDXS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CDXS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EXOZ — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LFCR — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LYEL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · LYEL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · LYEL — Implied EBITDA margin -1137459.3% outside the plausible band [-100%, 80%] (effect: quarantined) · LYEL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LYEL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LYEL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LYEL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · MGNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · MGNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · MGNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / Revenue on CY2027E consensus (6 of 11 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Contract Development and Manufacturing (CDMO) and it clears the coverage gate with 8 of 11 companies (73%). EV / EBITDA is carried as a cross-check. A revenue lens is used rather than a profit multiple because only 2 of 11 companies carry a meaningful forward EBITDA, too few to form a median. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 2 of 11 companies; EV / rEVenue: 8 of 11 companies; P/E: 0 of 11 companies. 1 company shows a non-meaningful EV / EBITDA denominator and is excluded from that statistic. 8 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥14.1x, Core 1.7x–14.1x, Discount <1.7x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 6.2x = median(ev_revenue CY2027E) (6 rated companies) · 16.5x = median(ev_revenue CY2027E) within Premium tier (n=2) · 6.2x = median(ev_revenue CY2027E) within Core tier (n=2) · 0.9x = median(ev_revenue CY2027E) within Discount tier (n=2) · 35% = median Rule of 40 score (revenue growth + EBITDA margin) (n=2)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Contract Development and Manufacturing (CDMO) recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 62 transactions were recorded for this industry; 18 are shown. 44 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 31 × deal value unit unresolved; 25 × no evidence record; 2 × duplicate precedent id; 8 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 318 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Contract Development and Manufacturing (CDMO)?

Company valuation reports run the same method against a single business — public or private.